Highly Experienced Life Sciences Executive That Brings Large Pharma and Biotech Experience
Evox Therapeutics Ltd, a leading exosome therapeutics company, announces that John McHutchison has joined its Board of Directors. John will be joining the Board as the representative for Oxford Sciences Innovation (OSI), one of the Company’s major shareholders. John is a highly experienced life sciences executive, with expertise across multiple therapeutic areas, particularly infectious diseases and diseases of the liver and gastrointestinal tract.
Recommended AI News: Voyager Digital Announces Assets Under Management Crossed USD$500 Million
John is currently Chief Executive Officer and President of Assembly Biosciences, a clinical-stage biotechnology company committed to advancing novel therapeutics to improve treatment options for hepatitis B virus worldwide. Prior to this, he spent nine years at Gilead Sciences, where most recently he was Chief Scientific Officer and Head of Research & Development. At Gilead he led the organization in the successful filing of numerous New Drug Applications (NDAs) and supplemental label updates across multiple therapeutic areas. Before this, he held various positions at Duke University Medical Center. John received his degrees in medicine and surgery from the University of Melbourne in Australia and in 2018 was recognized as an Officer of the Order of Australia for his distinguished service to medical research.
Recommended AI News: ClearPoint Neuro Announces First Procedure Utilizing ClearPoint 2.0 Software
Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented:
“We are delighted to have John join our Board of Directors. He has significant relevant experience in developing new products, particularly related to diseases of the liver. I am confident that this expertise will be invaluable as we look to advance our exosome therapeutics into the clinic and enter the next stage of growth.”
Commenting on his appointment, John McHutchison said:
“I’m very pleased to be joining the Board of Evox. The Company’s exosome-based platform is highly exciting and has incredible potential – I look forward to working with the rest of the team to help advance their product pipeline into the clinic.”
Recommended AI News: LTE and 5G Wireless Standards Continue to Evolve with Each New 3GPP Release
Copper radiator recycling Copper scrap environmental regulations Scrap metal procurement
Copper cable scrap market trends, Scrap metal recapturing and recycling, Scrap copper communication
Scrap metal material handling Ferrous material recycling licenses Iron scrap brokering
Ferrous material transportation vehicles, Iron disposal solutions, Metal salvage center